Journal
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
Volume 21, Issue 20, Pages -Publisher
MDPI
DOI: 10.3390/ijms21207549
Keywords
CLK; cdc-like kinase; inhibitor; chemical biology; tool compound; chemical probe; T3; SGC-CLK-1; MU1210; SM08502
Funding
- European Structural and Investment Funds
- Operational Programme Research, Development and Education, Preclinical Progression of New Organic Compounds with Targeted Biological Activity [CZ.02.1.01/0.0/0.0/16_025/0007381]
- National Program of Sustainability II (MEYS CR) [LQ1605]
- project CZ-OPENSCREEN: National Infrastructure for Chemical Biology [LM2015063]
- Bader Philanthropies
Ask authors/readers for more resources
Protein kinases represent a very pharmacologically attractive class of targets; however, some members of the family still remain rather unexplored. The biology and therapeutic potential of cdc-like kinases (CLKs) have been explored mainly over the last decade and the first CLK inhibitor, compound SM08502, entered clinical trials only recently. This review summarizes the biological roles and therapeutic potential of CLKs and their heretofore published small-molecule inhibitors, with a focus on the compounds' potential to be utilized as quality chemical biology probes.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
